2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane | 871464-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane
• CAS: 871464-67-4
• 化学式: C₁₁H₁₃ClN₂
• 分子量: 208.691
• InChiKey: LJEDQDIXPVICLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  tert-butyl 5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.03h， 生成 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane
  参考文献：
  名称：

  [EN] KINASE MODULATORS AND METHODS OF USE
  [FR] MODULATEURS DES PROTEINES KINASES ET LEURS METHODES D'UTILISATION

  摘要：

  公开号：

  WO2005117909A3

文献信息

• CGRP RECEPTOR ANTAGONISTS
  申请人：Stump Craig A.

  公开号：US20120010193A1

  公开（公告）日：2012-01-12

  Compounds of Formula (I) (wherein variables A 1 , A 2 , A 3 , ring-B, m, n, J, E 1 , E 2 , E 3 , R 5 , RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.

  公式（I）的化合物（其中变量A1，A2，A3，环B，m，n，J，E1，E2，E3，R5，RPG和Y如本文所述），其作为CGRP受体拮抗剂有用，并且在治疗或预防涉及CGRP受体的疾病方面有用，例如头痛，特别是偏头痛和集群头痛。本发明还涉及包含公式（I）化合物的制药组合物以及在预防或治疗涉及CGRP受体的疾病方面使用这些化合物和组合物。
• KINASE MODULATORS AND METHODS OF USE
  申请人：Exelixis, Inc.

  公开号：EP1750727A2

  公开（公告）日：2007-02-14
• Kinase Modulators and Methods of Use
  申请人：Anand Neel K.

  公开号：US20080076774A1

  公开（公告）日：2008-03-27

  The present invention relates to compounds of the Formula (I) and (II) wherein R, R 21 , R 25 -R 33 , m, n, X 21 -X 23 , and Q 1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.
• US20140275017A1
  申请人：——

  公开号：US20140275017A1

  公开（公告）日：2014-09-18
• US8076338B2
  申请人：——

  公开号：US8076338B2

  公开（公告）日：2011-12-13